title: Clinical research for curing ankylosing spondylitis through combining etanercept, thalidomide and sulfasalazine.
abstract: This article is to explore the curative effect of treating ankylosing spondylitis (AS) through combining etanercept, thalidomide and sulfasalazine. Sixty-two patients with AS were divided into 3 groups: experimental group Ais treated by etanercept+ thalidomide + sulfasalazine for 1 year (n=22); control group B was treated with etanercept; control group C was treated with thalidomide + sulfasalazine for 1 year (n=20). In 1st, 3rd, 6th, 12th month after the treatment, ASAS20 and ASAS50 were obtained through Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), erythrocyte sedimentation rate (ESR), C react protein (CRP) and then curative effect was analyzed. In 1 and 3 months after the treatment, each indicator had downtrend, and ASAS20 of experimental group and etanercept control group reached 100%; ASAS50 increased compared with the first months' treatment; although ASAS20 and ASAS50 in thalidomide control group was smaller, they increased; in 6 and 12 months after the treatment, ASAS20 improvement ratio in group A still remained on 100%, ASA50 improvement ratio increased; recurrence rate of group B increased; ASA20 and ASA50 had a continuous and significant increase, but its their was less than group A. This study proved that, the effect of curing AS combiningetanercept, thalidomide and sulfasalazine is better, therefore, it is a high-feasible treatment approach.
authors: Department of Orthopedics, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors: Peng
authors: P
authors: Xiao
authors: Department of Orthopedics, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors: Changhe
authors: C
authors: Pang
authors: Department of Orthopedics, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors: Xu
authors: X
authors: Zhu
authors: Department of Orthopedics, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors: Xuejian
authors: X
authors: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D012460:Sulfasalazine / Q000008:administration & dosage*; D013792:Thalidomide / Q000008:administration & dosage*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D012460:Sulfasalazine; D013792:Thalidomide; D000068800:Etanercept